Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis

The quality of randomization of Chinese randomized trials on herbal medicines for hepatitis B was assessed. Search strategy and inclusion criteria were based on the published protocol. One hundred and seventy-six randomized clinical trials (RCTs) involving 20,452 patients with chronic hepatitis B virus (HBV) infection were identified that tested Chinese medicinal herbs. They were published in 49 Chinese journals. Only 10% (18/176) of the studies reported the method by which they randomized patients. Only two reported allocation concealment and were considered as adequate. Twenty percent (30/150) of the studies were imbalanced at the 0.05 level of probability for the two treatments and 13.3% (20/150) imbalanced at the 0.01 level in the randomization. It is suggested that there may exist misunderstanding of the concept and the misuse of randomization based on the review.

Download Full-text

Study on Herbal Medicines, Ascorbic Acid, Cyanocobalamin, Tenofovir, Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B: A Combination of Treatment with Herbs

10.9734/bpi/nfmmr/v12/12532d ◽

2021 ◽

pp. 65-69

Author(s):

Nguyen Thi Trieu ◽

Tran Minh Duc

Keyword(s):

Ascorbic Acid ◽

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Herbal Medicines

Download Full-text

Methodology and study outcome of Chinese randomised trials on herbal medicines for chronic hepatitis B

BMC News and views ◽

10.1186/2048-4623-1-s3-pb106 ◽

2001 ◽

Vol 1 (S3) ◽

Author(s):

Jianping Liu ◽

Lise Lotte Kjaergard ◽

Christian Gluud

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Herbal Medicines ◽

Randomised Trials

Download Full-text

Anti-Inflammatory Drugs Reduce the Risk of Hepatocellular Carcinoma Development

ISRN Oncology ◽

10.5402/2011/390676 ◽

2011 ◽

Vol 2011 ◽

pp. 1-5 ◽

Cited By ~ 1

Author(s):

Yasushi Rino ◽

Kazuo Tarao

Keyword(s):

Hepatocellular Carcinoma ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Liver Diseases ◽

Herbal Medicines ◽

High Serum ◽

Hcv Rna ◽

Inflammatory Processes ◽

Ifn Therapy ◽

Inflammatory Drugs

Nowadays, patients with chronic hepatitis C in all countries are generally treated with interferon (IFN), and more than 50% of patients become HCV-RNA negative following PEG-IFN plus ribavirin therapy, but unfortunately, the IFN therapy is not effective in about 70% of patients with HCV-associated LC. In Japan, HCC actually develops in about 7% of those patients every year. A strategy for preventing HCC development other than IFN therapy is, therefore, urgently needed for those patients. We reported that the recurrence rate and the development of HCC was more rapid in the high serum ALT level (>80 IU) patients with HCV-associated LC. Sho-saiko-to, Juzen-taiho-to, and stronger-neo minophagen C are herbal medicines used in Japan to treat chronic viral liver diseases, and they work by reducing inflammatory processes and controlling ALT levels. Aggressive reduction therapy for ALT levels in HCV-LC patients could significantly prevent HCC development.

Download Full-text